Cargando…

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A

It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated blood platelets mediate the primary response to vascular injury, we hypothesize that storage of coagulation Factor VIII within platelets may provide a locally inducible treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Lily M., Nurden, Paquita, Nurden, Alan T., Nichols, Timothy C., Bellinger, Dwight A., Jensen, Eric S., Haberichter, Sandra L., Merricks, Elizabeth, Raymer, Robin A., Fang, Juan, Koukouritaki, Sevasti B., Jacobi, Paula M., Hawkins, Troy B., Cornetta, Kenneth, Shi, Qizhen, Wilcox, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Pub. Group 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868233/ https://www.ncbi.nlm.nih.gov/pubmed/24253479 http://dx.doi.org/10.1038/ncomms3773

Ejemplares similares

Inherited thrombocytopenias: history, advances and perspectives
por: Nurden, Alan T., et al.
Publicado: (2020)

Deep Vein Thrombosis, Raynaud's Phenomenon, and Prinzmetal Angina in a Patient with Glanzmann Thrombasthenia
por: Nurden, Alan, et al.
Publicado: (2012)

Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy
por: Nurden, Paquita, et al.
Publicado: (2020)

The Nbeal2(−/−) mouse as a model for the gray platelet syndrome
por: Deppermann, Carsten, et al.
Publicado: (2013)

Molecular Dynamics Analysis of a Novel β3 Pro189Ser Mutation in a Patient with Glanzmann Thrombasthenia Differentially Affecting αIIbβ3 and αvβ3 Expression
por: Laguerre, Michel, et al.
Publicado: (2013)

Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-Related Disorders
por: Saposnik, Béatrice, et al.
Publicado: (2014)

A single F153Sβ3 mutation causes constitutive integrin αIIbβ3 activation in a variant form of Glanzmann thrombasthenia
por: Koukouritaki, Sevasti B., et al.
Publicado: (2023)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Phenotype analysis and clinical management in a large family with a novel truncating mutation in RASGRP2, the CalDAG‐GEFI encoding gene
por: Desai, Amrita, et al.
Publicado: (2017)

Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A
por: Al-Banaa, Kadhim, et al.
Publicado: (2021)

Porcine and Canine von Willebrand Factor and von Willebrand Disease: Hemostasis, Thrombosis, and Atherosclerosis Studies
por: Nichols, Timothy C., et al.
Publicado: (2010)

APOLD1 loss causes endothelial dysfunction involving cell junctions, cytoskeletal architecture, and Weibel-Palade bodies, while disrupting hemostasis
por: Stritt, Simon, et al.
Publicado: (2022)

Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet
por: Nichols, Timothy C., et al.
Publicado: (2015)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Glanzmann thrombasthenia
por: Nurden, Alan T
Publicado: (2006)

Profiling the Genetic and Molecular Characteristics of Glanzmann Thrombasthenia: Can It Guide Current and Future Therapies?
por: Nurden, Alan
Publicado: (2021)

The GPIIb-IIIa defect of platelets in Glanzmann thrombasthenia
por: Nurden, Alan T.
Publicado: (2023)

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
por: Escobar, Miguel, et al.
Publicado: (2021)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial
por: Gruppo, Ralph, et al.
Publicado: (2019)

Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories
por: Sommer, J M, et al.
Publicado: (2014)

Identification of a novel mutation in the factor VIII gene causing severe haemophilia A
por: Nissen, S. K., et al.
Publicado: (2018)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa
por: Nichols, Timothy C., et al.
Publicado: (2020)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

Ex vivo factor VIII‐modified proliferating human hepatocytes therapy for haemophilia A
por: Zhang, Kun, et al.
Publicado: (2023)

Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test – Demonstrated in vitro and ex vivo
por: Madsen, Daniel Elenius, et al.
Publicado: (2017)

Inflammation and haemostasis
por: Margetic, Sandra
Publicado: (2012)

Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers
por: Yoo, Ki-Young, et al.
Publicado: (2022)

Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
por: Borchiellini, Alessandra, et al.
Publicado: (2021)

Subunit Flexibility of Multimeric von Willebrand Factor/Factor VIII Complexes
por: Parker, Ernest T., et al.
Publicado: (2022)

Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients
por: van Moort, Iris, et al.
Publicado: (2020)

Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic‐pharmacodynamic model for patients with haemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

In silico analysis of structural modifications in and around the integrin αIIb genu caused by ITGA2B variants in human platelets with emphasis on Glanzmann thrombasthenia
por: Pillois, Xavier, et al.
Publicado: (2018)

Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia
por: Zaher, Galila, et al.
Publicado: (2012)

Successful transfemoral prosthesis in a patient with haemophilia A and factor VIII inhibitors: A case report
por: Chao, Ta-Chung, et al.
Publicado: (2023)

Exome sequencing identifies NBEAL2 as the causative gene for Gray Platelet Syndrome
por: Albers, Cornelis A, et al.
Publicado: (2011)

Disturbances of Haemostasis in Diabetes Mellitus
por: Fattah, Mohamed A., et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_o96bj31upiopluip56mvhu1v8t